HL60, U937, K562, 32Dcl3 and HEK293T cells obtained from ATCC were cultured as previously described [13 (link), 23 (link), 29 (link), 42 (link)]. siMNT (Smartpool: ON-TARGET plus MNT SiRNA L-009373-00-0010), scrambled siRNA and siRNA transfection reagent DhermaFECT (ThermoScientific T-2001-03) were purchased from Dhermacon RNA technologies (Lafayette, CO, USA). shMNT (TRCN00000234786), shE6AP (TRCN0000235499) and shRNA control were purchased from Sigma. Expression plasmids for HA-MNT [43 (link)], pcDNA3.1-E6AP [10 (link)], pCAG-HA-E6AP-C843A [44 (link)], pGEX4T-GST-E6AP [45 (link)] were kind gifts from G. Meroni, Nihar Jana, Ikuo Shoji and Zafar Nawaz, respectively. Transfections in adherent cells were performed using Lipofectamine-LTX and Plus Reagent (15338-100; Invitrogen) as per manufacture`s protocol as previously described [13 (link), 42 (link)]; Transfections in myeloid cells HL60 and U937 were performed using AMAXA cell Nucleofector kit V (VCA-1003; Lonza). E6AP-C843A-HA is a catalytically inactive mutant of E6AP [13 (link)]. Cells were treated with 10μM MG132 (Z-Leu-Leu-Leu-al, Sigma, St.Louis, MO) and 10μM Lactacystin (Sigma) 6h prior to cell lysis.
Free full text: Click here